The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberrationThe beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberration
|
| 0 Comment
Regardless of current advances within the systemic therapy of metastatic gastric most cancers (GC), prognostic outcomes stay poor. Appreciable analysis effort has been invested in characterizing the genomic panorama of